Literature DB >> 29052157

A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models.

John Brazier1, Roberta Ara2, Donna Rowen2, Helene Chevrou-Severac3.   

Abstract

Generic preference-based measures (GPBMs) of health are used to obtain the quality adjustment weight required to calculate the quality-adjusted life year in health economic models. GPBMs have been developed to use across different interventions and medical conditions and typically consist of a self-complete patient questionnaire, a health state classification system, and preference weights for all states defined by the classification system. Of the six main GPBMs, the three most frequently used are the Health Utilities Index version 3, the EuroQol 5 dimensions (3 and 5 levels), and the Short Form 6 dimensions. There are considerable differences in GPBMs in terms of the content and size of descriptive systems (i.e. the numbers of dimensions of health and levels of severity within these), the methods of valuation [e.g. time trade-off (TTO), standard gamble (SG)], and the populations (e.g. general population, patients) used to value the health states within the descriptive systems. Although GPBMs are anchored at 1 (full health) and 0 (dead), they produce different health state utility values when completed by the same patient. Considerations when selecting a measure for use in a clinical trial include practicality, reliability, validity and responsiveness. Requirements of reimbursement agencies may impose additional restrictions on suitable measures for use in economic evaluations, such as the valuation technique (TTO, SG) or the source of values (general public vs. patients).

Entities:  

Mesh:

Year:  2017        PMID: 29052157     DOI: 10.1007/s40273-017-0545-x

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  29 in total

1.  Using a discrete choice experiment to estimate health state utility values.

Authors:  Nick Bansback; John Brazier; Aki Tsuchiya; Aslam Anis
Journal:  J Health Econ       Date:  2011-12-06       Impact factor: 3.883

2.  Comparing utility scores before and after hearing-aid provision : results according to the EQ-5D, HUI3 and SF-6D.

Authors:  Garry R Barton; John Bankart; Adrian C Davis; Quentin A Summerfield
Journal:  Appl Health Econ Health Policy       Date:  2004       Impact factor: 2.561

3.  A comparison of methods for converting DCE values onto the full health-dead QALY scale.

Authors:  Donna Rowen; John Brazier; Ben Van Hout
Journal:  Med Decis Making       Date:  2014-11-14       Impact factor: 2.583

Review 4.  International Regulations and Recommendations for Utility Data for Health Technology Assessment.

Authors:  Donna Rowen; Ismail Azzabi Zouraq; Helene Chevrou-Severac; Ben van Hout
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

5.  The impact of age-related macular degeneration on health status utility values.

Authors:  Mireia Espallargues; Carolyn J Czoski-Murray; Nicholas J Bansback; Jill Carlton; Grace M Lewis; Lindsey A Hughes; Christopher S Brand; John E Brazier
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-11       Impact factor: 4.799

Review 6.  EQ-5D as a quality of life measure in people with dementia and their carers: evidence and key issues.

Authors:  Natalia Hounsome; Martin Orrell; Rhiannon Tudor Edwards
Journal:  Value Health       Date:  2011 Mar-Apr       Impact factor: 5.725

7.  An evaluation of patient-reported outcome measures in lower limb reconstruction surgery.

Authors:  M Burton; S J Walters; M Saleh; J E Brazier
Journal:  Qual Life Res       Date:  2011-12-18       Impact factor: 4.147

Review 8.  Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey.

Authors:  Louise Longworth; Yaling Yang; Tracey Young; Brendan Mulhern; Mónica Hernández Alava; Clara Mukuria; Donna Rowen; Jonathan Tosh; Aki Tsuchiya; Pippa Evans; Anju Devianee Keetharuth; John Brazier
Journal:  Health Technol Assess       Date:  2014-02       Impact factor: 4.014

9.  An Australian discrete choice experiment to value eq-5d health states.

Authors:  Rosalie Viney; Richard Norman; John Brazier; Paula Cronin; Madeleine T King; Julie Ratcliffe; Deborah Street
Journal:  Health Econ       Date:  2013-06-13       Impact factor: 3.046

10.  Testing a discrete choice experiment including duration to value health states for large descriptive systems: addressing design and sampling issues.

Authors:  Nick Bansback; Arne Risa Hole; Brendan Mulhern; Aki Tsuchiya
Journal:  Soc Sci Med       Date:  2014-05-20       Impact factor: 4.634

View more
  33 in total

Review 1.  An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis.

Authors:  Matthew Franklin; James Lomas; Simon Walker; Tracey Young
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

Review 2.  A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement.

Authors:  Jihyung Hong; Eun-Young Bae
Journal:  Pharmacoeconomics       Date:  2021-07-28       Impact factor: 4.981

3.  Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?

Authors:  David John Mott
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

4.  Heath State Utility Values for Cost-Effectiveness Models.

Authors:  Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

Review 5.  Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies.

Authors:  Roberta Ara; John Brazier; Tracey Young
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

6.  Special Edition on Utility Measurement, PharmacoEconomics.

Authors:  Andrew Lloyd
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

Review 7.  The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment.

Authors:  Donna Rowen; John Brazier; Roberta Ara; Ismail Azzabi Zouraq
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

Review 8.  The Identification, Review and Synthesis of Health State Utility Values from the Literature.

Authors:  Roberta Ara; John Brazier; Tessa Peasgood; Suzy Paisley
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

9.  Modifying the quality-adjusted life year calculation to account for meaningful change in health-related quality of life: insights from a pragmatic clinical trial.

Authors:  Nathan S McClure; Mike Paulden; Arto Ohinmaa; Jeffrey A Johnson
Journal:  Eur J Health Econ       Date:  2021-06-05

10.  The impact of common chronic conditions on health-related quality of life: a general population survey in Iran using EQ-5D-5L.

Authors:  Ali Akbari Sari; Fereshteh Karimi; Zahra Emrani; Hojjat Zeraati; Alireza Olyaeemanesh; Rajabali Daroudi
Journal:  Cost Eff Resour Alloc       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.